Extended Adjuvant Aromatase Inhibitor Therapy in Post-Menopausal Women.

about

Extended Adjuvant Aromatase Inhibitor Therapy in Post-Menopausal Women.

Item

http://www.wikidata.org/entity/Q49334420

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Extended Adjuvant Aromatase Inhibitor Therapy in Post-Menopausal Women.

@en

Extended Adjuvant Aromatase Inhibitor Therapy in Post-Menopausal Women.

@nl

type

Item

label

Extended Adjuvant Aromatase Inhibitor Therapy in Post-Menopausal Women.

@en

Extended Adjuvant Aromatase Inhibitor Therapy in Post-Menopausal Women.

@nl

prefLabel

Extended Adjuvant Aromatase Inhibitor Therapy in Post-Menopausal Women.

@en

Extended Adjuvant Aromatase Inhibitor Therapy in Post-Menopausal Women.

@nl

P1476

Extended Adjuvant Aromatase Inhibitor Therapy in Post-Menopausal Women.

@en

P2093

Maura N Dickler

http://www.w3.org/2001/XMLSchema#string

Stephen M Schleicher

http://www.w3.org/2001/XMLSchema#string

P2860

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

Triple-Negative Breast Cancer

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.

Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.

P2888

s12609-017-0260-9

P304

236-241

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12609-017-0260-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092241801

http://www.w3.org/2001/XMLSchema#string

P698

29399271

http://www.w3.org/2001/XMLSchema#string

P932

5791913

http://www.w3.org/2001/XMLSchema#string